Advertisement
UK markets open in 6 hours 29 minutes
  • NIKKEI 225

    38,098.44
    +546.28 (+1.45%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • CRUDE OIL

    83.43
    +0.07 (+0.08%)
     
  • GOLD FUTURES

    2,336.00
    -6.10 (-0.26%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • Bitcoin GBP

    53,398.70
    -217.17 (-0.41%)
     
  • CMC Crypto 200

    1,432.76
    +18.00 (+1.27%)
     
  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     
  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     

Post-Brexit Britain just got a £275 million investment from a drugs giant

Great Britain's Amy Williams following the Women's Skeleton Run 2 at Whistler Sliding Centre, Whistler, Canada.
Great Britain's Amy Williams following the Women's Skeleton Run 2 at Whistler Sliding Centre, Whistler, Canada.

Andrew Milligan / PA Archive/Press Association Images

Pharmaceuticals giant GlaxoSmithKline (GSK) is investing £275 million into its drug manufacturing network across Britain, a major vote of confidence in British industry in the post-Brexit era.

FTSE 100-listed GSK announced on Wednesday that it would invest the sum across three sites in Durham, Hertfordshire, and Scotland. The investment will go towards increasing production and will "support delivery of its latest innovative respiratory and large molecule biological medicines."

GSK, which has a market value of £81.3 billion, adds that: "The vast majority of these products will be for export to global markets." Brexit supporters have argued that the fall in the pound to a 31-year-low against the dollar in the wake of the vote to leave the European Union could actually boost exports as it makes British goods look cheaper to overseas buyers.

ADVERTISEMENT

However, a recent survey of British manufacturers found confidence in the sector at its worst since the financial crisis as a result of the EU referendum result.

GSK says: "The UK [is] an attractive location for investment in advanced manufacturing due to a number of factors including the skilled workforce, technological and scientific capabilities & infrastructure and a competitive corporate tax system."

Andrew Witty, CEO of GSK, says in a statement:

"Today’s announcement reflects further investment to support our pharmaceutical pipeline and meet growing demand for our innovative portfolio of newly launched products. It is testament to our skilled UK workforce and the country’s leading position in life sciences that we are making these investments in advanced manufacturing here. From their manufacture in the UK, many of these medicines will be sent to patients around the world."

GSK says the investment will create new jobs but doesn't give a figure for how many exactly. The company employs 6,000 people across the UK.

Since Britain voted to leave the EU on June 23, business activity in the UK has been mixed. While most banks and economists are predicting a recession, two major corporate takeovers have been announced — ARM Holdings and VocaLink — and US bank Wells Fargo announced the acquisition of a £300 million new London headquarters.

In all cases, many people have suggested the fall in the pound could have played a part in making the assets more attractive to buyers, due to their reduced price tag.

NOW WATCH: 50 Cent will pay $23.4 million to creditors over the next 5 years — here's how he made and lost millions

See Also:

SEE ALSO: Britain's manufacturers haven't been this depressed since the financial crisis

DON'T MISS: One bleak chart shows how awful the next few years will be for the British economy